CDRH Gets Specific About RF Cardiac Ablation Indications At RAPS
This article was originally published in The Gray Sheet
FDA plans to issue a new guidance on general versus specific indications and product labeling, according to CDRH Office of Device Evaluation Director Daniel Schultz
You may also be interested in...
Sponsors of surgical devices that have been 510(k) cleared for general indications should collect clinical data for specific procedures if they are cited as examples in physician training, ODE posits
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.